#AntifibroticTherapy
LightNews LightNews
gmj-georgia.bsky.social
New hope for IPF patients: landmark trial shows a novel therapy can slow lung function decline in idiopathic pulmonary fibrosis. Published in NEJM July 202…

#Antifibrotictherapy #Idiopathicpulmonaryfibrosis #IPFtreatment #Lungdisease #NEJM2026

#Antifibrotictherapy #Idiopathicpulmonaryfibrosis #…
IPF breakthrough: new drug slows lung decline
New hope for IPF patients: landmark trial shows a novel therapy can slow lung function decline in idiopathic pulmonary fibrosis. Published in NEJM July 202… #Antifibrotictherapy #Idiopathicpulmonaryfibrosis #IPFtreatment #Lungdisease #NEJM2026
news.gmj.ge
September 25, 2026 at 3:26 PM
currentmedscience.bsky.social
This article is a comprehensive overview of #Pharmacological effects & mechanisms of #Emodin in inhibiting #FibroticDisease & emphasizes its #therapeutic advantages, systemic pathways & #Translational potential as a candidate for #AntifibroticTherapy. #medsky

To read: doi.org/10.1007/s115...
Emodin: A Promising Natural Compound for Combating Fibrotic Diseases
May 16, 2026 at 2:30 PM
jrheumatol.bsky.social
Editorial

Practical Issues Relating to the Use of Antifibrotic Therapy in Patients With Interstitial Lung Disease and Rheumatoid Arthritis

📖 doi.org/10.3899/jrhe...

#antifibrotictherapy #interstitiallungdisease #rheumatoidarthritis
May 2, 2025 at 2:31 PM
rarediseaseadvisor.bsky.social
#AntifibroticTherapy in #InterstitialLungDisease, which includes #ProgressivePulmonaryFibrosis (#PPF), may improve patients’ quality of life by reducing certain symptoms, although the overall certainty of evidence remains limited. @tarespirdis.bsky.social

Read more: https://bit.ly/44kikLg
Antifibrotics Show Potential Benefits in ILD, Despite Low Certainty of Evidence
Antifibrotic therapy in ILD may improve patients' QoL by reducing certain symptoms, though the overall certainty of evidence remains limited.
bit.ly
December 15, 2025 at 4:52 PM
rarediseaseadvisor.bsky.social
#Deupirfenidone (LYT-100), a next-generation #AntifibroticTherapy, demonstrated a favorable safety and efficacy profile across age groups of adults with #IPF, including patients aged 75 years and older. @accpchest.bsky.social

Read here: https://bit.ly/49pnRn4

#RareDisease #MedSky #CHEST2025
Deupirfenidone Well Tolerated and Effective in Older Patients With IPF
Deupirfenidone demonstrated a favorable safety and efficacy profile across age groups in IPF, including patients aged 75 years and older.
bit.ly
October 28, 2025 at 6:32 PM